Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies

Pharmacogenomics. 2010 Mar;11(3):449-57. doi: 10.2217/pgs.10.14.

Abstract

Misassignment between DNA samples and clinical or epidemiological data may compromise the results of genetic association studies. Genotyping in replicates or controlling for Hardy-Weinberg equilibrium cannot identify misassignments caused by sample mix-ups. DNA-based sex identification (sex typing) is currently the best strategy to identify mix-ups. Here we review the available methods and present validated protocols for sex typing. The protocols are based on single-nucleotide differences between the human amelogenin genes, AMELX and AMELY, and are optimized for real-time PCR (TaqMan), primer-extension (SNaPshot) and PCR-RFLP genotyping platforms. In addition, we review the limitations of the sex-typing strategy, including a limited ability to identify single sample mix-ups, the dependence of the power of this approach on the sex distribution in the study population, and rare genetic conditions. Alternative strategies for mix-up identification and possible consequences of mix-up identification are also discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Amelogenin / genetics*
  • Base Sequence
  • DNA / genetics*
  • DNA / isolation & purification
  • DNA Primers / genetics
  • Female
  • Genetic Association Studies / methods*
  • Genetic Association Studies / standards*
  • Humans
  • Male
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Polymorphism, Single Nucleotide
  • Quality Control
  • Sex Determination Analysis

Substances

  • AMELX protein, human
  • AMELY protein, human
  • Amelogenin
  • DNA Primers
  • DNA